Abstract
Objectives
To compare the efficacy of oral Montelukast and inhaled Budesonide as a first line preventive therapy in mild persistent asthma in age group 2–18 y.
Methods
This prospective randomized controlled clinical study was conducted for 12 wk. Sixty patients of mild persistent asthma aged 2 to 18 y were randomly allocated to either oral Montelukast (n = 60) or inhaled Budesonide (n = 60) group. Outcomes measured were improvement in peak expiratory flow rate (PEFR), forced expiratory volume 1 s/forced vital capacity (FEV1/FVC), day time and night time symptoms and frequency of exacerbations and need to change medications.
Results
There was significant improvement in PEFR, FEV1/FVC, day time and night time symptoms and frequency of exacerbations in both groups. However, more significant improvement in FEV1/FVC (CI 95 %, p = 0.029) and day time symptoms (CI 95 %, p = 0.002) was seen in Budesonide group compared to Montelukast group.
Conclusions
The present study suggests that oral Montelukast is not inferior to Budesonide in treatment of mild persistent asthma in 2 to 18 y children in terms of control of symptoms and improvement in pulmonary function tests over a 12 wk period. However, there was more significant improvement in day time symptoms, more significant increase in FEV1/FVC ratio and less exacerbation in patients receiving Budesonide compared to those receiving Montelukast. However, side effects due to long term use of steroids such as growth stunting and bone osteopenia should also be considered before recommending. Trial registered at CTRI no. REF/2012/09/004035
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ducharme F, di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. The Cochrane Library2008, Issue 4.
Pal R, Dahal S, Pal S. Prevalence of bronchial asthma in Indian children. Indian J Community Med. 2009;34:310–6.
Amado MC, Portnoy JM. Diagnosing asthma in young children. Curr Opin Allergy Clin Immunol. 2006;6:101–5.
Lodha R, Puranik M, Kattal N, Kabra SK. Social and economic impact of childhood asthma. Indian Pediatr. 2003;40:874–9.
Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda, MD: National Heart, Lung and Blood Institute, 2002 (NIH Publication 02–3659). www.ginasthma.com/.
National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma-summary report 2007. J Allergy Clin Immunol. 2007;120:S94–138.
PJ Sharek, D Bergman, FM Ducharme. The effect of Beclomethasone on height in children. 2011 - summaries.cochrane.org.
Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999;340:197–206.
Knorr B, Matz J, Bernstien JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Monteleukast for chronic asthma in 6 to 14 year old children: A randomized, double blind trial. JAMA. 1998;279:1181–6.
Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48.
Walia M, Lodha R, Kabra SK. Montelukast in pediatric asthma management. Indian J Pediatr. 2006;73:275–82.
Kukreja S, Sanjay S, Ghosh G, Aggarwal KK, Moharana A. Montelukast - evaluation in 6 to 14 years old children with persistent asthma - Pediatric montelukast study group. Indian J Pediatr. 2004;71:811–5.
Israel E, Chervinsky PS, Friedman B, Van Bavel J, Skalky CS, Ghannam AF, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol. 2002;110:847–54.
Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol. 2002;109:68–74.
Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, et al. Randomized controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58:211–6.
Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6 to 14-year-old patients with mild asthma: The MOSAIC study. Pediatrics. 2005;116:360–9.
Szefler SJ, Baker JW, Uryniak T, Goldman M, et al. Comparative study of budesonide inhalation suspension and Montelukast in young children with mild persistent asthma. J Allergy Clin Immunol. 2007;120:1043–50.
Karaman Ö, Sünneli L, Uzuner N, Islekel H, Turgut CS, Köse S, et al. Evaluation of Monteleukast in 8 to 14 year old children with mild persistent asthma and compared with inhaled corticosteroids. Allergol Immunopathol (Madr). 2004;32:21–7.
Wallerstedt SM, Brunlöf G, Sundström A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf. 2009;18:858–64. doi:10.1002/pds.1794.
Bibby S, Healy B, Steele R, Kumareswaran K, Nelson H, Beasley R. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: A analysis of the FDA AERS database. Thorax. 2010;65:132–8. doi:10.1136/thx.2009.120972.
Contributions
MBS: Did principle investigation; JG: Guided, gathered knowledge and collected the data; SK: Did data collection; JD: Did spirometry excercise and interpretation. Dr. Jayendra Gohil will act as guarantor for this paper.
Conflict of Interest
None.
Role of Funding Source
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shah, M.B., Gohil, J., Khapekar, S. et al. Montelukast versus Budesonide as a First Line Preventive Therapy in Mild Persistent Asthma in 2 to 18 y. Indian J Pediatr 81, 655–659 (2014). https://doi.org/10.1007/s12098-013-1334-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-013-1334-y